Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia

Bone Marrow Transplantation

Volumn 26, Issue 6, 2000, Pages 607-614

  Baker, K S ^a   Bostrom, B ^b   Defor, T ^a   Ramsay, N K C ^a   Woods, W G ^c   Blazar, B R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^c South Carolina Cancer Center   (United States)

Author keywords

Acute myelogenous leukemia; Busulfan; Pharmacokinetics

Indexed keywords

ACICLOVIR; BUSULFAN; COTRIFAMOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ARTICLE; AUTOTRANSPLANTATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PEROPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; STEADY STATE;

EID: 0033804614     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702590     Document Type: Article

References (40)

1. Pretransplant conditioning with busulfan (Myleran) and cyclophosphamide for nonmalignant diseases. Assessment of engraftment following histocompatible allogeneic bone marrow transplantation
2. Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogenic bone marrow transplantation
3. Marrow transplantation for thalassaemia following busulphan and cyclophosphamide
4. Aspects concerning busulfan pharmacokinetics and bioavailability
5. Pharmacokinetics of high-dose busulfan in children
6. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology
7. Busulfan disposition in children
8. Busulfan disposition below the age of three: Alteration in children with lysosomal storage disease
9. Chronopharmacology of high-dose busulfan in children
10. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation
11. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders
12. Busulfan
13. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics
14. Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation
15. Busulfan bioavailability
16. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?
17. Optimization of busulfan dosage in children undergoing bone marrow transplantation: A pharmacokinetic study of dose escalation
18. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation
19. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide
20. Bone marrow transplantation in the busulfin-treated rat. III. Relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients
21. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children
22. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels
23. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics
24. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation
25. Association of busulfan area under the curve with veno-occlusive disease following BMT
26. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
27. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients
28. Dose-dependent neurotoxicity of high-dose busulfan in children: A clinical and pharmacological study
29. Graft-versus-host disease: Pathophysiological and clinical aspects
30. Acute upper gastrointestinal graft-versus-host disease: Clinical significance and response to immunosuppressive therapy
31. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia
32. Nonparametric estimation from incomplete observations
33. Regression models and life-tables
34. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia
35. Growth in children undergoing bone marrow transplantation after busulfan and cyclophosphamide conditioning
36. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: The impact of conditioning regimen without total-body irradiation - A report from the de Greffe de Moelle
37. Growth after bone marrow transplantation in young children conditioned with chemotherapy alone
38. Decreased incidence of and risk factor for hepatic veno-occlusive disease with an intravenous busulfan (BU) containing preparative regimen for hematopoietic stem cell transplantation (HSCT)
39. Allogeneic hemopoietic stem cell transplantation (BMT) after IV busulfan, and cyclophosphamide (BuCy) for acute myeloid leukemia (AML) and myelodysplasia (MDS)
40. Intravenous (IV) vs. oral busulfan (BU) as part of a BU/CY (cyclophosphamide) preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT): Decreased incidence of hepatic veno-occlusive disease (VOD)